Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

This clinical trial is a Phase II study investigating the effectiveness and safety of a three-drug combination-Zeprumetostat, Azacitidine, and Mitoxantrone Hydrochloride Liposome-in adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL is an aggressive type of non-Hodgkin lymphoma that has limited treatment options after the first line of therapy. The study aims to enroll approximately 26 patients at a single center in China. Eligible participants will receive up to 6 cycles of induction therapy with all three drugs, followed by up to 2 years of maintenance therapy with Z

Trial Details

NCT ID
NCT07372352
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • Zeprumetostat
  • Azacitidine (AZA)
  • Mitoxantrone Hydrochloride Liposome
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Relapsed or refractory peripheral T-cell lymphoma after first-line or higher treatment.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.
  • Presence of measurable target lesions \[Note: Target lesions are defined as lesions with at least one longest diameter (LD) measurement \> 1.5 cm a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →